Kris, Mark Gregory

Publications

Sort by

Co-Author Network

selected publications

Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. JAMA oncology. 2020 Academic Article GET IT
Times cited: 80
COVID-19 in patients with lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 152
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2020 Academic Article GET IT
Times cited: 28
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 100
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 57
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 6
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Comment GET IT
Times cited: 169
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 15
Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease. Annals of surgery. 2019 Academic Article GET IT
Times cited: 19
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 73
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 171
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 79
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 193
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Cold Spring Harbor molecular case studies. 2019 Academic Article GET IT
Times cited: 16
"A Tool, Not a Crutch": Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering. Journal of oncology practice. 2019 Academic Article GET IT
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 70
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 200
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Academic Article GET IT
Times cited: 99
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 300
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 218
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 222
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 35
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung cancer (Amsterdam, Netherlands). 2018 Academic Article GET IT
Times cited: 31
Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer discovery. 2018 Academic Article GET IT
Times cited: 114
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 164
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 882
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 236
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer. 2017 Academic Article GET IT
Times cited: 22
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nature communications. 2017 Academic Article GET IT
Times cited: 116
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung cancer (Amsterdam, Netherlands). 2017 Academic Article GET IT
Times cited: 31
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery. 2017 Academic Article GET IT
Times cited: 399
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 36
KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. The American journal of surgical pathology. 2016 Academic Article GET IT
Times cited: 43
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 331
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung cancer (Amsterdam, Netherlands). 2016 Review GET IT
Times cited: 10
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Academic Article GET IT
Times cited: 30
Reply to J. Jupp et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Letter GET IT
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers. Lung cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 40
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 49
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 81
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Academic Article GET IT
Times cited: 4
Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails". JAMA oncology. 2016 Academic Article GET IT
Times cited: 34
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical lung cancer. 2016 Academic Article GET IT
Times cited: 100
Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. PloS one. 2016 Academic Article GET IT
Times cited: 15
Comparison of CT volumetric measurement with RECIST response in patients with lung cancer. European journal of radiology. 2016 Academic Article GET IT
Times cited: 40
Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 30
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 182
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer. 2015 Academic Article GET IT
Times cited: 74
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. 2015 GET IT
Times cited: 126
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 1340
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 69
Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clinical trials (London, England). 2015 Academic Article GET IT
Times cited: 33
Antiemetics: American Society of Clinical Oncology Focused Guideline Update. 2015 GET IT
Times cited: 172
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. 2015 GET IT
Times cited: 34
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 47
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015 Academic Article GET IT
Times cited: 11
EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. 2015 GET IT
Times cited: 81
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer. 2015 Academic Article GET IT
Times cited: 156
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 294
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer discovery. 2015 Academic Article GET IT
Times cited: 114
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 225
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 86
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. Cancer. 2015 Academic Article GET IT
Times cited: 14
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 87
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 207
Non-small cell lung cancer, version 1.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Academic Article GET IT
Times cited: 144
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 113
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 97
Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway. Clinical lung cancer. 2014 Academic Article GET IT
Times cited: 3
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib. 2014 GET IT
Times cited: 23
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2014 Academic Article GET IT
Times cited: 93
A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 31
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung cancer (Amsterdam, Netherlands). 2014 Academic Article GET IT
Times cited: 44
Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. The American journal of surgical pathology. 2014 Academic Article GET IT
Times cited: 118
Comprehensive long-term care of patients with lung cancer: development of a novel thoracic survivorship program. The Annals of thoracic surgery. 2014 Academic Article GET IT
Times cited: 22
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clinical lung cancer. 2014 Academic Article GET IT
Times cited: 52
Small-cell lung cancers in patients who never smoked cigarettes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 89
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 Academic Article GET IT
Times cited: 1259
Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014 Academic Article GET IT
Times cited: 542
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 161
Chemotherapy for lung cancers: here to stay. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2014 Review GET IT
Times cited: 6
Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer. Cancer biomarkers : section A of Disease markers. 2014 Academic Article GET IT
Times cited: 20
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 71
Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 1
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 100
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 11
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 104
Non-small cell lung cancer, version 2.2013. 2013 GET IT
Times cited: 356
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. 2013 GET IT
Times cited: 56
Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 33
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer discovery. 2013 Academic Article GET IT
Times cited: 413
Characteristics of lung cancers harboring NRAS mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 116
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 1891
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 267
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Molecular cancer therapeutics. 2013 Academic Article GET IT
Times cited: 331
Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2013 Academic Article GET IT
Times cited: 52
Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 25
Toxicity of initial chemotherapy in older patients with lung cancers. Journal of geriatric oncology. 2013 Academic Article GET IT
Times cited: 17
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 148
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012 Academic Article GET IT
Times cited: 85
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 159
Non-small cell lung cancer. 2012 GET IT
Times cited: 320
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 444
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer discovery. 2012 Academic Article GET IT
Times cited: 582
Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 33
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. Journal of the National Cancer Institute. 2012 Academic Article GET IT
Times cited: 106
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Molecular cancer therapeutics. 2012 Academic Article GET IT
Times cited: 42
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 2012 Academic Article GET IT
Times cited: 117
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 381
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 364
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer. 2012 Academic Article GET IT
Times cited: 46
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 34
The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. Journal of the National Comprehensive Cancer Network : JNCCN. 2012 Review GET IT
Times cited: 60
Antiemesis. 2012 GET IT
Times cited: 50
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 18
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 203
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 318
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 132
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Editorial Article GET IT
Times cited: 21
Malignant pleural mesothelioma. 2012 GET IT
Times cited: 35
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 135
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 86
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Molecular cancer therapeutics. 2011 Academic Article GET IT
Times cited: 176
Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 7
Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting. Clinical advances in hematology & oncology : H&O. 2011 Academic Article GET IT
Times cited: 10
Antiemetics: american society of clinical oncology clinical practice guideline update. Journal of oncology practice. 2011 Academic Article GET IT
Times cited: 43
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. 2011 GET IT
Times cited: 648
Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas. Lung cancer (Amsterdam, Netherlands). 2011 Academic Article GET IT
Times cited: 48
Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 49
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-oncology. 2011 Academic Article GET IT
Times cited: 293
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 356
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 56
Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer immunology, immunotherapy : CII. 2011 Academic Article GET IT
Times cited: 43
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 114
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science translational medicine. 2011 Academic Article GET IT
Times cited: 425
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 124
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 63
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2011 Academic Article GET IT
Times cited: 81
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 57
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 561
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 231
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 24
A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed. 2011 GET IT
Times cited: 14
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 109
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2011 Academic Article GET IT
Times cited: 782
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 118
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 510
Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion. Clinical advances in hematology & oncology : H&O. 2011 Academic Article GET IT
Times cited: 9
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Academic Article GET IT
Times cited: 110
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 531
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 54
Thymic malignancies. 2010 GET IT
Times cited: 13
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. The Journal of thoracic and cardiovascular surgery. 2010 Academic Article GET IT
Times cited: 30
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Academic Article GET IT
Times cited: 78
Insulin-like growth factor-1 receptor expression in thymic malignancies. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Academic Article GET IT
Times cited: 42
Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2010 Conference Paper GET IT
Times cited: 34
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Academic Article GET IT
Times cited: 72
Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2010 Review GET IT
Times cited: 538
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 92
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal of neuro-oncology. 2010 Academic Article GET IT
Times cited: 91
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Conference Paper GET IT
Times cited: 589
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer chemotherapy and pharmacology. 2010 Academic Article GET IT
Times cited: 65
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2010 Academic Article GET IT
Times cited: 120
Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer. 2010 Academic Article GET IT
Times cited: 103
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 72
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR. American journal of roentgenology. 2010 Academic Article GET IT
Times cited: 107
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 699
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. Journal of the National Cancer Institute. 2009 Academic Article GET IT
Times cited: 429
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Review GET IT
Times cited: 108
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 152
Integration of molecular profiling into the lung cancer clinic. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 72
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer chemotherapy and pharmacology. 2009 Academic Article GET IT
Times cited: 49
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 2009 Academic Article GET IT
Times cited: 481
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009 Academic Article GET IT
Times cited: 261
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2009 Academic Article GET IT
Times cited: 4
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Cancer chemotherapy and pharmacology. 2009 Academic Article GET IT
Times cited: 52
Antiemesis. Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2009 Conference Paper GET IT
Times cited: 28
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Archives of pathology & laboratory medicine. 2009 Academic Article GET IT
Times cited: 46
Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clinical nephrology. 2009 Academic Article GET IT
Times cited: 84
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 103
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 42
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 467
DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 59
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature medicine. 2008 Academic Article GET IT
Times cited: 877
Foreword; challenging the 'one-size-fits-all' approach of chemotherapy and radiotherapy for patients with non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2008 Article GET IT
Times cited: 2
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. The American journal of surgical pathology. 2008 Academic Article GET IT
Times cited: 345
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. The Journal of molecular diagnostics : JMD. 2008 Academic Article GET IT
Times cited: 166
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 283
Non-small cell lung cancer. 2008 GET IT
Times cited: 33
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 104
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008 Academic Article GET IT
Times cited: 224
Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. The Annals of thoracic surgery. 2008 Academic Article GET IT
Times cited: 9
Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008 Review GET IT
Times cited: 23
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 70
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 148
Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Academic Article GET IT
Times cited: 933
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. 2007 GET IT
Times cited: 316
Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007 Academic Article GET IT
Times cited: 29
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 266
Pulmonary toxicity associated with erlotinib. 2007 GET IT
Times cited: 75
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer. 2007 Academic Article GET IT
Times cited: 93
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007 Academic Article GET IT
Times cited: 11
Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed. Journal of the National Cancer Institute. 2007 Editorial Article GET IT
Times cited: 29
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PloS one. 2007 Academic Article GET IT
Times cited: 80
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 30
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007 Academic Article GET IT
Times cited: 25
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 111
Antiemesis. 2007 GET IT
Times cited: 46
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 108
Lung cancer: computerized quantification of tumor response--initial results. Radiology. 2006 Academic Article GET IT
Times cited: 102
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung cancer (Amsterdam, Netherlands). 2006 Academic Article GET IT
Times cited: 63
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 726
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. The Lancet. Oncology. 2006 Academic Article GET IT
Times cited: 447
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2006 Conference Paper GET IT
Times cited: 26
Molecular on/off switch. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 10
Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 66
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer. 2006 Academic Article GET IT
Times cited: 70
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2006 Academic Article GET IT
Times cited: 48
EGFR mutations in small-cell lung cancers in patients who have never smoked. The New England journal of medicine. 2006 Letter GET IT
Times cited: 226
Non-small cell lung cancer clinical practice guidelines in oncology. 2006 GET IT
Times cited: 145
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Conference Paper GET IT
Times cited: 679
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 199
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 657
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 92
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Annals of oncology : official journal of the European Society for Medical Oncology. 2005 Conference Paper GET IT
Times cited: 301
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer. 2005 Academic Article GET IT
Times cited: 68
Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005 Academic Article GET IT
Times cited: 505
New approaches in the management of lung cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2005 Academic Article GET IT
Times cited: 1
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 579
How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. The oncologist. 2005 Academic Article GET IT
Times cited: 24
A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer chemotherapy and pharmacology. 2005 Academic Article GET IT
Times cited: 23
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 1421
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005 Academic Article GET IT
Times cited: 221
Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer immunology, immunotherapy : CII. 2005 Academic Article GET IT
Times cited: 43
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer. 2005 Academic Article GET IT
Times cited: 148
Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005 Academic Article GET IT
Times cited: 176
A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life?. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2005 Academic Article GET IT
Times cited: 62
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 119
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 2005 GET IT
Times cited: 3130
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 107
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS medicine. 2005 Academic Article GET IT
Times cited: 1383
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2004 Review GET IT
Times cited: 107
Practical management of patients with non-small-cell lung cancer treated with gefitinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 164
Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). 2004 GET IT
Times cited: 16
SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma. The Annals of thoracic surgery. 2004 Review GET IT
Times cited: 17
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 118
Antiemesis clinical practice guidelines in oncology. 2004 GET IT
Times cited: 8
Update: NCCN non-small cell lung cancer clinical practice guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
Times cited: 11
Phase I study of green tea extract in patients with advanced lung cancer. Cancer chemotherapy and pharmacology. 2004 Academic Article GET IT
Times cited: 81
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?. Journal of the National Cancer Institute. 2004 Editorial Article GET IT
Times cited: 36
Squamous cell carcinoma related oncogene regulates angiogenesis through vascular endothelial growth factor-A. Annals of surgical oncology. 2004 Academic Article GET IT
Times cited: 20
Lung cancer in US women: a contemporary epidemic. JAMA. 2004 Review GET IT
Times cited: 230
Predictors of clinical response of non-small cell cancer to gefitinib. JAMA. 2004 Letter GET IT
Times cited: 1
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 723
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Seminars in cancer biology. 2004 Review GET IT
Times cited: 59
Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 108
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003 Academic Article GET IT
Times cited: 2505
Why do we need another antiemetic? Just ask. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Editorial Article GET IT
Times cited: 36
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 73
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 46
Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. American journal of clinical oncology. 2003 Review GET IT
Times cited: 27
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 59
A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2003 Academic Article GET IT
Times cited: 56
Variations in lung cancer risk among smokers. Journal of the National Cancer Institute. 2003 Academic Article GET IT
Times cited: 497
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung cancer (Amsterdam, Netherlands). 2003 Academic Article GET IT
Times cited: 30
Targeting lethal minimal residual disease in small cell lung cancer. Seminars in oncology. 2003 Review GET IT
Times cited: 5
Management of lung cancer in older adults. CA: a cancer journal for clinicians. 2003 Review GET IT
Times cited: 110
New approaches in the treatment of non-small cell lung cancer: taxanes in the treatment of NSCLC: pathways to progress. Lung cancer (Amsterdam, Netherlands). 2002 Editorial Article GET IT
Times cited: 4
A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung cancer (Amsterdam, Netherlands). 2002 Academic Article GET IT
Times cited: 94
Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. The Annals of thoracic surgery. 2002 Academic Article GET IT
Times cited: 146
The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease. Cancer. 2002 Academic Article GET IT
Times cited: 21
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers. Seminars in oncology. 2002 Review GET IT
Times cited: 4
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 758
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 154
Antiemetic guidelines: creating a more practical treatment approach. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2002 Academic Article GET IT
Times cited: 90
Trastuzumab in the treatment of non-small cell lung cancer. Seminars in oncology. 2002 Review GET IT
Times cited: 36
Chemotherapy for early stage non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2001 Review GET IT
Times cited: 6
Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. The Annals of thoracic surgery. 2001 Academic Article GET IT
Times cited: 277
New drug and multimodality combinations in the treatment of advanced non--small cell lung cancer. Seminars in oncology. 2001 Review GET IT
Times cited: 4
Small molecule inhibitors of the epidermal growth factor receptor in patients with non-small-cell lung cancer: an update of clinical data from the 2001 American Society of Clinical Oncology meeting. Clinical lung cancer. 2001 Academic Article GET IT
Development of inhalational agents for oncologic use. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Review GET IT
Times cited: 93
Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 3
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update. Seminars in oncology. 2001 Academic Article GET IT
Times cited: 6
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Seminars in oncology. 2001 Review GET IT
Times cited: 51
NCCN: Non-small cell lung cancer. Cancer control : journal of the Moffitt Cancer Center. 2001 Conference Paper GET IT
Times cited: 17
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 781
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 31
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Academic Article GET IT
Times cited: 62
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 1317
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Seminars in oncology. 2000 Review GET IT
Times cited: 30
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. The Journal of thoracic and cardiovascular surgery. 2000 Academic Article GET IT
Times cited: 239
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma. Cancer. 2000 Academic Article GET IT
Times cited: 12
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 65
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Academic Article GET IT
Times cited: 57
Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer journal (Sudbury, Mass.). 2000 Academic Article GET IT
Times cited: 73
The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia. Cancer. 1999 Academic Article GET IT
Times cited: 34
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 94
Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma. Cancer. 1999 Academic Article GET IT
Times cited: 9
Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination. Seminars in oncology. 1999 Review GET IT
Times cited: 16
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. 1999 GET IT
Times cited: 628
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer. Seminars in oncology. 1999 Academic Article GET IT
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 167
Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1999 Academic Article GET IT
Times cited: 96
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 1999 Academic Article GET IT
Times cited: 9
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. The New England journal of medicine. 1999 Academic Article GET IT
Times cited: 338
Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer. The Journal of thoracic and cardiovascular surgery. 1999 Academic Article GET IT
Times cited: 81
Oral cisapride for the control of delayed vomiting following high-dose cisplatin. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1999 Academic Article GET IT
Times cited: 5
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. American journal of clinical oncology. 1998 Academic Article GET IT
Times cited: 25
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 739
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1998 Review GET IT
Times cited: 4
What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer?. Seminars in oncology. 1998 Academic Article GET IT
Times cited: 14
Consensus regarding multiple day and rescue antiemetic therapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1998 Conference Paper GET IT
Times cited: 12
Delayed emesis following anticancer chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1998 Conference Paper GET IT
Times cited: 34
Don't be mis-guided when the data are silent and the editorial misses the mark. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Letter GET IT
Times cited: 1
Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 58
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 1997 Academic Article GET IT
Times cited: 53
NCCN antiemesis practice guidelines. Oncology (Williston Park, N.Y.). 1997 Academic Article GET IT
Times cited: 51
A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung cancer (Amsterdam, Netherlands). 1997 Review GET IT
Times cited: 47
The role of multimodality therapy in locoregional non-small cell lung cancer. Surgical oncology clinics of North America. 1997 Review GET IT
Times cited: 21
Lung cancer cure, care, and cost: let the data be your guide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Editorial Article GET IT
Times cited: 2
Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. Seminars in oncology. 1997 Academic Article GET IT
Times cited: 1
The development of docetaxel (Taxotere) in non-small cell lung cancer. Seminars in oncology. 1997 Academic Article GET IT
Times cited: 4
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in Cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1997 Academic Article GET IT
Times cited: 7
Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1997 Academic Article GET IT
Times cited: 185
Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. Journal of the National Cancer Institute. 1997 Letter GET IT
Times cited: 88
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 27
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Times cited: 187
Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer chemotherapy and pharmacology. 1997 Academic Article GET IT
Times cited: 16
Proposal for classifying the acute emetogenicity of cancer chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Review GET IT
Times cited: 552
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer. 1996 Review GET IT
Times cited: 38
High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996 Academic Article GET IT
Times cited: 2
NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. 1996 GET IT
Times cited: 64
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 148
Metabolic phenotypes of retinoic acid and the risk of lung cancer. Cancer research. 1996 Academic Article GET IT
Times cited: 15
Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996 Academic Article GET IT
Times cited: 66
Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. European journal of nuclear medicine. 1996 Academic Article GET IT
Times cited: 42
Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer research. 1995 Academic Article GET IT
Times cited: 187
Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. Cancer. 1995 Academic Article GET IT
Times cited: 6
Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 26
Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy. American journal of clinical oncology. 1995 Academic Article GET IT
Times cited: 5
New chemotherapeutic agents for non-small cell lung cancer. Chest. 1995 Review GET IT
Times cited: 17
Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. American journal of clinical oncology. 1995 Academic Article GET IT
Times cited: 27
Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). Lung cancer (Amsterdam, Netherlands). 1995 Review GET IT
Times cited: 9
Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung cancer (Amsterdam, Netherlands). 1995 Review GET IT
Times cited: 43
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 1995 Academic Article GET IT
Times cited: 123
Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer chemotherapy and pharmacology. 1995 Academic Article GET IT
Times cited: 25
New antineoplastic agents in lung cancer 1988-1993. Cancer treatment and research. 1995 Review GET IT
Times cited: 1
Delayed emesis following anticancer chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1994 Review GET IT
Times cited: 49
Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer. Journal of surgical oncology. 1994 Academic Article GET IT
Times cited: 43
Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1994 Review GET IT
Times cited: 77
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 228
Randomized phase II trial comparing two versus three doses of ondansetron when used in combination with dexamethasone in patients receiving cisplatin > or = 100 mg/m2. American journal of clinical oncology. 1994 Academic Article GET IT
Times cited: 3
Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1994 Academic Article GET IT
Times cited: 72
Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer. 1994 Academic Article GET IT
Times cited: 193
The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. Cancer. 1994 Academic Article GET IT
Times cited: 5
Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer chemotherapy and pharmacology. 1994 Academic Article GET IT
Times cited: 55
Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting. Important advances in oncology. 1994 Review GET IT
Times cited: 7
Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 93
Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone. Cancer. 1993 Review GET IT
Times cited: 22
Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy. Cancer. 1993 Academic Article GET IT
Midazolam in patients receiving anticancer chemotherapy and antiemetics. Journal of pain and symptom management. 1993 Academic Article GET IT
Times cited: 5
Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 120
Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. The Annals of thoracic surgery. 1993 Academic Article GET IT
Times cited: 384
Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2. American journal of clinical oncology. 1993 Academic Article GET IT
Times cited: 2
Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer. Investigational new drugs. 1993 Academic Article GET IT
Times cited: 11
Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy. Cancer. 1993 Academic Article GET IT
Times cited: 6
Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy. Cancer chemotherapy and pharmacology. 1993 Academic Article GET IT
Times cited: 4
Edatrexate, an antifolate with antitumor activity: a review. Cancer investigation. 1993 Review GET IT
Times cited: 41
Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). European journal of cancer (Oxford, England : 1990). 1993 Academic Article GET IT
Times cited: 265
Tropisetron (ICS 205-930): a selective 5-hydroxytryptamine antagonist. European journal of cancer (Oxford, England : 1990). 1993 Review GET IT
Times cited: 7
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. The Journal of thoracic and cardiovascular surgery. 1992 Academic Article GET IT
Times cited: 17
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Cancer. 1992 Review GET IT
Times cited: 65
Phase II trials of ondansetron with high-dose cisplatin. Seminars in oncology. 1992 Review GET IT
Times cited: 6
Phase II trials of small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Letter GET IT
Times cited: 1
Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations. Seminars in oncology. 1992 Review GET IT
Times cited: 12
Phase II trials in small-cell lung cancer: shouldn't we be doing better?. Journal of the National Cancer Institute. 1992 Editorial Article GET IT
Times cited: 5
Dose-ranging trial of zacopride: the emetic antiemetic?. Journal of the National Cancer Institute. 1992 Academic Article GET IT
Times cited: 1
Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Review GET IT
Times cited: 65
Management of nausea and vomiting caused by anticancer drugs: state of the art. Oncology (Williston Park, N.Y.). 1992 Review GET IT
Times cited: 2
A reappraisal of the role of prophylactic cranial irradiation in limited small cell lung cancer. International journal of radiation oncology, biology, physics. 1992 Academic Article GET IT
Times cited: 34
Induction chemotherapy for non-small cell lung cancer with clinically evident mediastinal node metastases: the role of postoperative radiotherapy. International journal of radiation oncology, biology, physics. 1992 Academic Article GET IT
Times cited: 14
Twice daily thoracic irradiation for limited small cell lung cancer. International journal of radiation oncology, biology, physics. 1991 Academic Article GET IT
Times cited: 11
Limited small-cell lung cancer: do favorable short-term results predict ultimate outcome?. American journal of clinical oncology. 1991 Academic Article GET IT
Times cited: 4
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. The New England journal of medicine. 1991 Academic Article GET IT
Times cited: 1270
Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer. Investigational new drugs. 1991 Academic Article GET IT
Times cited: 2
Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. American journal of clinical oncology. 1991 Academic Article GET IT
Times cited: 9
Limited small cell lung cancer: prognostic significance of a complete response to the induction phase of chemotherapy followed by thoracic irradiation. Radiology. 1991 Academic Article GET IT
Times cited: 2
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. Journal of the National Cancer Institute. 1991 Academic Article GET IT
Times cited: 279
Methodology in anti-emetic trials. European journal of cancer (Oxford, England : 1990). 1991 Academic Article GET IT
Times cited: 30
Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate. Journal of cancer research and clinical oncology. 1991 Academic Article GET IT
Times cited: 35
Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Annals of neurology. 1990 Academic Article GET IT
Times cited: 373
Dose-ranging antiemetic trial of high-dose oral metoclopramide. American journal of clinical oncology. 1989 Academic Article GET IT
Times cited: 8
Antiemetic therapy: management of chemotherapy-induced nausea and vomiting. Seminars in oncology nursing. 1989 Academic Article GET IT
Times cited: 4
Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer. American journal of clinical oncology. 1989 Academic Article GET IT
Times cited: 18
Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. Journal of the National Cancer Institute. 1989 Academic Article GET IT
Times cited: 85
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989 Academic Article GET IT
Times cited: 230
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. Cancer research. 1988 Academic Article GET IT
Times cited: 52
Chemotherapy in non-small cell lung cancer: results of recent trials. Seminars in oncology. 1988 Review GET IT
Times cited: 33
Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C: a randomized trial with placebo in patients receiving cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988 Academic Article GET IT
Times cited: 19
Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988 Academic Article GET IT
Times cited: 98
The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). The Annals of thoracic surgery. 1988 Academic Article GET IT
Times cited: 152
Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988 Academic Article GET IT
Times cited: 75
Controlling emesis in patients receiving cancer chemotherapy. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1988 Review GET IT
Times cited: 10
Peaks, valleys, and plateaus in small cell lung cancer. Cancer investigation. 1988 Editorial Article GET IT
Preliminary results of combination chemotherapy and sequential accelerated fractionation radiation therapy in limited-stage small cell carcinoma of the lung. Evaluation of measures for reduction of toxicity and effect on complete response rate. Antibiotics and chemotherapy. 1988 Academic Article GET IT
Times cited: 1
Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer. 1987 Academic Article GET IT
Times cited: 129
Preoperative and adjuvant chemotherapy in locally advanced non-small cell lung cancer. The Surgical clinics of North America. 1987 Academic Article GET IT
Times cited: 16
Bronchoalveolar lavage cell populations in bleomycin lung toxicity. Thorax. 1987 Academic Article GET IT
Times cited: 39
Acute chest pain syndrome during bleomycin infusions. Cancer. 1987 Academic Article GET IT
Times cited: 40
The management of chemotherapy-induced nausea and vomiting. The Medical clinics of North America. 1987 Review GET IT
Times cited: 75
Phase II trial of esorubicin in patients with advanced non-small cell lung cancer. Cancer treatment reports. 1987 Academic Article GET IT
Times cited: 5
Phase II trial of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer. Cancer treatment reports. 1987 Academic Article GET IT
Times cited: 14
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1986 Academic Article GET IT
Times cited: 221
Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer treatment reports. 1986 Academic Article GET IT
Times cited: 89
Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer treatment reports. 1986 Academic Article GET IT
Times cited: 137
Simultaneous estimation of liquid and solid gastric emptying using radiolabelled egg and water in supine normal subjects. International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology. 1986 Academic Article GET IT
Times cited: 4
Phase 1 trial of levonantradol in chemotherapy-induced emesis. American journal of clinical oncology. 1985 Academic Article GET IT
Times cited: 14
Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 72
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1985 Academic Article GET IT
Times cited: 314
Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer. American journal of clinical oncology. 1985 Academic Article GET IT
Times cited: 13
Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 84
Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment. Chest. 1985 Academic Article GET IT
Times cited: 24
Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer. 1985 Academic Article GET IT
Times cited: 181
Relationship of Auer rods and chromosome findings to outcome in eighty-nine adults with acute nonlymphoblastic leukemia. Leukemia research. 1985 Academic Article GET IT
Times cited: 6
Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer treatment reports. 1984 Academic Article GET IT
Times cited: 88
Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy. 1984 GET IT
Times cited: 28
Phase I trial of PCNU. Cancer treatment reports. 1983 Academic Article GET IT
Times cited: 2
Phase II trial of PCNU in non-small cell lung cancer. Cancer treatment reports. 1983 Academic Article GET IT
Times cited: 7
Extrapyramidal reactions with high-dose metoclopramide. The New England journal of medicine. 1983 Letter GET IT
Times cited: 131
Phase II trial of 4'-epi-doxorubicin in patients with non-small cell lung cancer. Cancer treatment reports. 1983 Academic Article GET IT
Times cited: 21
Respiratory alkalosis and abdominal pain heralding Candida hepatitis: occurrence in patients with acute leukemia in remission. Archives of internal medicine. 1982 Academic Article GET IT
Times cited: 8
Medicine in a disrupted society: the role of the academic medical center. The American journal of medicine. 1981 Academic Article GET IT

more ...

less ...

Background

education and training

M.D., Cornell University Medical College 1977
B.A., Fordham University 1973

Contact

full name

Mark Gregory Kris

VIVO Weill Cornell Medical College

Mark Gregory Kris Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name